Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Instil Bio (TIL)
NASDAQ:TIL
Holding TIL?
Track your performance easily
TIL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.07 - $92.00
Previous Close$26.91
Volume91.62K
Average Volume (3M)310.29K
Market Cap
$175.61M
Enterprise Value$138.83M
Total Cash (Recent Filing)$120.36M
Total Debt (Recent Filing)$83.58M
Price to Earnings (P/E)―
Beta6.97
Next Earnings
Mar 10, 2025EPS Estimate
-$2.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.55
Shares Outstanding6,525,887
10 Day Avg. Volume163,855
30 Day Avg. Volume310,288
Standard Deviation0.63
R-Squared0.02
Alpha0.00425
Financial Highlights & Ratios
Price to Book (P/B)0.86
Price to Sales (P/S)114.52
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue92.99
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.06
Forecast
1Y Price Target
$145.00Price Target Upside438.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Instil Bio News
PremiumCompany Announcements
Instil Bio Outlines Oncology Strategy and Collaborative EffortsBulls Say, Bears Say
Bulls Say
Market PotentialIncreased investor interest in the PD-1xVEGF space is seen as supportive of building enthusiasm for the mechanism, with Instil shares expected to rise as enthusiasm grows.
Product DevelopmentSYN-2510 is positioned as the third most advanced asset in its class, with clinical data already produced and an IND expected soon, suggesting Instil shares are poised to rise.
ValuationRecent acquisitions by major companies highlight a valuation gap for Instil, suggesting it is undervalued.
Bears Say
Clinical TrialsThe timeline delay for the U.S. trial is due to CRO contract negotiations and hiring of clinical development employees.
EarningsA net loss for 3Q24 of $3.54 per share was reported versus an estimated net loss of $3.08 per share.
Market PerceptionThe stock is characterized as speculative risk, indicating a higher level of uncertainty and potential volatility.
---
TIL FAQ
What was Instil Bio’s price range in the past 12 months?
Instil Bio lowest stock price was $6.07 and its highest was $92.00 in the past 12 months.
What is Instil Bio’s market cap?
Currently, no data Available
When is Instil Bio’s upcoming earnings report date?
Instil Bio’s upcoming earnings report date is Mar 10, 2025 which is in 79 days.
How were Instil Bio’s earnings last quarter?
Instil Bio released its earnings results on Nov 13, 2024. The company reported -$2.55 earnings per share for the quarter, missing the consensus estimate of -$2.108 by -$0.442.
Is Instil Bio overvalued?
According to Wall Street analysts Instil Bio’s price is currently Undervalued.
Does Instil Bio pay dividends?
Instil Bio does not currently pay dividends.
What is Instil Bio’s EPS estimate?
Instil Bio’s EPS estimate is -$2.48.
How many shares outstanding does Instil Bio have?
Instil Bio has 6,525,887 shares outstanding.
What happened to Instil Bio’s price movement after its last earnings report?
Instil Bio reported an EPS of -$2.55 in its last earnings report, missing expectations of -$2.108. Following the earnings report the stock price went down -5.512%.
Which hedge fund is a major shareholder of Instil Bio?
Among the largest hedge funds holding Instil Bio’s share is Perceptive Advisors LLC. It holds Instil Bio’s shares valued at 23M.
---
Instil Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$145.00 (438.83% Upside)
$145.00 (438.83% Upside)
Hedge Fund Trend
Increased
By 345.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 22.5%
Last 30 Days ▼ 22.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
290.56%
12-Months-Change
Fundamentals
Return on Equity
-36.63%
Trailing 12-Months
Asset Growth
-19.90%
Trailing 12-Months
Company Description
Instil Bio
Instil Bio Inc is a clinical-stage cell therapy company. It is developing tumor infiltrating lymphocytes for the treatment of cancer.
---
TIL Stock 12 Month Forecast
Average Price Target
$145.00
▲(438.83% Upside)
Technical Analysis
Best Analysts Covering TIL
1 Year
1 Year Success Rate
6/17 ratings generated profit
1 Year Average Return
-9.64%
reiterated a buy rating 2 months ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of -9.64% per trade.
---